https://www.biospace.com/fresenius-kabi-further-expands-oncology-portfolio-with-launch-of-cyclophosphamide-for-injection-usp
Fresenius Kabi Further Expands Oncology Portfolio with Launch of Cyclophosphamide for Injection,...
Feb 28, 2024 - Fresenius Kabi announced today it has introduced Cyclophosphamide for Injection, USP, a generic substitute for Cytoxan, for use in treating several forms of...
fresenius kabioncology portfolio
https://www.biospace.com/merck-kgaa-darmstadt-germany-strengthens-oncology-portfolio-through-commercialization-agreement-with-abbisko-for-phase-iii-asset-pimicotinib
Merck KGaA, Darmstadt, Germany Strengthens Oncology Portfolio Through Commercialization Agreement...
Dec 4, 2023 - Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a license agreement with Abbisko Therapeutics Co. Ltd., Shanghai,...
merck kgaadarmstadt germanyoncology portfoliocommercializationagreement
https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-to-acquire-chimerix-further-diversifying-oncology-portfolio-302393056.html
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX) ("Chimerix"), today announced the companies...
jazz pharmaceuticalsacquirediversifyingoncologyportfolio
https://www.amgen.com/newsroom/press-releases/2023/10/amgen-to-present-new-research-from-oncology-portfolio-and-pipeline-at-esmo-2023
AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023| Amgen
https://www.takeda.com/newsroom/press-releases/2023/takeda-to-present-oncology-portfolio-and-pipeline-data-at-the-2023-asco-annual-meeting-and-eha-congress/
Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA...
Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its expanding oncology pipeline and established product portfolio at the 59th Annual...